Market Closed -
Australian S.E.
07:12:50 27/06/2024 am IST
|
5-day change
|
1st Jan Change
|
0.039
AUD
|
+8.33%
|
|
0.00%
|
-11.36%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
10.67
|
14.89
|
48.06
|
25.82
|
11.48
|
Enterprise Value (EV)
1 |
6.06
|
11.61
|
33.9
|
18.61
|
6.566
|
P/E ratio
|
-6.25
x
|
-5.18
x
|
-15.1
x
|
-2.47
x
|
-10.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
315
x
|
-
|
50.1
x
|
-
|
2.32
x
|
EV / Revenue
|
179
x
|
-
|
35.4
x
|
-
|
1.33
x
|
EV / EBITDA
|
-3.88
x
|
-4.02
x
|
-10.6
x
|
-1.78
x
|
-5.9
x
|
EV / FCF
|
-7.27
x
|
-9.24
x
|
-22.7
x
|
-6.05
x
|
-3.33
x
|
FCF Yield
|
-13.8%
|
-10.8%
|
-4.41%
|
-16.5%
|
-30%
|
Price to Book
|
2.11
x
|
4.08
x
|
3.29
x
|
4.68
x
|
2.45
x
|
Nbr of stocks (in thousands)
|
73,581
|
78,385
|
1,43,472
|
1,43,472
|
1,43,472
|
Reference price
2 |
0.1450
|
0.1900
|
0.3350
|
0.1800
|
0.0800
|
Announcement Date
|
30/08/19
|
28/08/20
|
27/08/21
|
29/08/22
|
25/08/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.0289
|
0.0338
|
-
|
0.9588
|
-
|
4.953
|
EBITDA
1 |
-0.8889
|
-1.562
|
-2.885
|
-3.203
|
-10.44
|
-1.114
|
EBIT
1 |
-0.9318
|
-1.618
|
-2.941
|
-3.265
|
-10.5
|
-1.171
|
Operating Margin
|
-3,227.03%
|
-4,779.14%
|
-
|
-340.53%
|
-
|
-23.65%
|
Earnings before Tax (EBT)
1 |
-0.9314
|
-1.659
|
-2.869
|
-3.178
|
-10.44
|
-1.069
|
Net income
1 |
-0.9314
|
-1.659
|
-2.869
|
-3.178
|
-10.44
|
-1.069
|
Net margin
|
-3,225.59%
|
-4,900.92%
|
-
|
-331.45%
|
-
|
-21.58%
|
EPS
2 |
-0.0301
|
-0.0232
|
-0.0367
|
-0.0221
|
-0.0727
|
-0.007448
|
Free Cash Flow
1 |
-0.149
|
-0.8336
|
-1.256
|
-1.494
|
-3.076
|
-1.971
|
FCF margin
|
-515.89%
|
-2,462.8%
|
-
|
-155.84%
|
-
|
-39.79%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
31/08/18
|
30/08/19
|
28/08/20
|
27/08/21
|
29/08/22
|
25/08/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
0.1
|
4.61
|
3.29
|
14.2
|
7.22
|
4.91
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-0.15
|
-0.83
|
-1.26
|
-1.49
|
-3.08
|
-1.97
|
ROE (net income / shareholders' equity)
|
-147%
|
-57.3%
|
-65.9%
|
-34.8%
|
-104%
|
-20.9%
|
ROA (Net income/ Total Assets)
|
-83.9%
|
-34.1%
|
-41.5%
|
-22%
|
-58.2%
|
-11.2%
|
Assets
1 |
1.11
|
4.867
|
6.913
|
14.46
|
17.93
|
9.508
|
Book Value Per Share
2 |
0.0200
|
0.0700
|
0.0500
|
0.1000
|
0.0400
|
0.0300
|
Cash Flow per Share
2 |
0
|
0.0600
|
0.0400
|
0.1000
|
0.0500
|
0.0300
|
Capex
|
-
|
0.02
|
0
|
0.03
|
0
|
-
|
Capex / Sales
|
-
|
56.37%
|
-
|
3.12%
|
-
|
-
|
Announcement Date
|
31/08/18
|
30/08/19
|
28/08/20
|
27/08/21
|
29/08/22
|
25/08/23
|
|
1st Jan change
|
Capi.
|
---|
| -11.36% | 34.61L | | +23.13% | 4.69TCr | | +37.94% | 3.91TCr | | -8.73% | 3.85TCr | | +28.09% | 3.1TCr | | -12.26% | 2.61TCr | | +10.57% | 2.59TCr | | +45.05% | 1.42TCr | | +32.23% | 1.25TCr | | -6.56% | 1.14TCr |
Other Biotechnology & Medical Research
|